Home Medizin Bio-Rad bringt vericheck ddPCR replikationskompetente Lentivirus- und replikationskompetente AAV-Kits für die Zell- und Gentherapieproduktion auf den Markt

Bio-Rad bringt vericheck ddPCR replikationskompetente Lentivirus- und replikationskompetente AAV-Kits für die Zell- und Gentherapieproduktion auf den Markt

von NFI Redaktion

Bio-Rad Laboratories, Inc. (NYSE: BIO und BIO.B), a global leader in life science research and clinical diagnostics products, recently announced the launch of the Vericheck ddPCR™ Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit.

These kits offer fast, cost-effective solutions for absolute quantification of replication competent lentivirus (RCL) and replication competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies.

Replication competent viruses (RCVs) have the ability to infect cells and replicate to produce additional virions. RCVs can be generated through recombination events between the transfer plasmid and either the production plasmids or the genome of the packaging cell line.

Ensuring the safety of new cell and gene therapies requires RCV testing of samples throughout the production process. The Bio-Rad Vericheck ddPCR kits for RCL and RCAAV detection provide a validated solution for highly specific and sensitive detection and quantification of viral replication genes that may indicate the presence of an RCV.

Designed for Bio-Rad’s QX Droplet Digital PCR platforms, the tests feature a simple workflow, including automated data analysis and flexible sample throughput. Compared to traditional cell culture-based methods for RCV testing, the kits significantly reduce costs and processing time, delivering results in just 8 hours.

“As the number of cell and gene therapies entering the market continues to rise, we see a growing emphasis on the need for products that ensure safety and efficacy throughout all production processes. We believe that Droplet Digital PCR solutions can help address this unmet need.”

Carolyn Reifsnyder, Senior Director of Marketing at Bio-Rad

Carolyn adds: “The launch of Bio-Rad’s latest Vericheck ddPCR kits for RCL and RCAAV detection into our expanding portfolio reflects our ongoing commitment to providing innovative QC tools to support advancements in the field of cell and gene therapy.”

To learn more about the Vericheck ddPCR kits for RCL and RCAAV detection, visit bio-rad.com/ddPCR-Vericheck-RCV.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.